CHEMICAL COMPOUNDS

摘要

1379781 N-furylmethyl-morphinane compounds BOEHRINGER INGELHEIM GmbH 18 Feb 1972 [19 Feb 1971] 7650/72 Heading C2C] Novel compounds of the Formula I wherein R denotes hydrogen, methyl or acetyl and R 1 denotes hydrogen, methyl or ethyl, and acid addition salts, racemic mixtures of optically active isomers, may be obtained (a) by reducing a compound of the formula (wherein Z is COOH, CHO, CH 2 OH, CH 3 CO, or -CH 2 CHO), or (b) by catalytic hydrogenation of a compound of Formula IVa (wherein Z is a halogen atom), (c) by methylating or acetylating a compound of Formula I (wherein R denotes a hydrogen atom), (d) by dealkylating, dearylating or deacylating a compound of Formula IVa where Z is R 1 and R1 is an alkyl, aralkyl or acyl group, (e) by reacting a compound of the Formula (II) (where R1 denotes H, alkyl, aralkyl or acyl), with a compound of the Formula (III) (wherein Z is H, halogen, CH 3 , C 2 H 5 , CHO, COOH, CH 2 OH, CH 3 CO, or -CH 2 CHO and X represents a halogen atom or an alkyl- or aryl-sulphonyloxy group), (f) by reacting a compound of Formula II with formaldehyde and a compound of Formula V (g) by reacting a compound of Formula II with a compound of the Formula VI (h) by reducing a compound of Formula (VIII), and where necessary in any of the above methods reducing Z to R 1 , dealkylating or deacylating R1 and converting to CH 3 or CH 3 CO. When Z is COOH it can be converted to H by decarboxylation with copper and quinoline. Pharmaceutical compositions having analgesic, anti-tussive and morphine antagonistic effects comprise a compound of Formula I or physiologically compatible salt thereof in association with a pharmaceutical carrier or excipient, in forms suitable for oral, rectal, enteral or parenteral administration.